What Is the Treatment of Secondary Raynaud's Phenomenon?
This protocol covers the first-line oral management of Secondary Raynaud's phenomenon (ICD-11 BD42.1). Several oral agents from distinct pharmacological classes are available, and the appropriate choice depends on the individual clinical picture.
Management involves oral agents from more than one pharmacological class — including at least one option with a profile that differs from the others and may be preferred when patients cannot tolerate conventional vasoactive therapies. The full selection of agents, their sequencing, and clinical decision points are set out in the complete protocol.
References
DOI: 10.1177/1759720X17740074
The evidence base for other oral therapies for RP is very weak, other drugs sometimes prescribed include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, α blockers, nitrates, and the selective serotonin receptor uptake inhibitor fluoxetine.
Fluoxetine has the advantage of not being associated with same vasodilatory side effects as the other drugs mentioned above and may therefore be beneficial in patients intolerant to other therapies.
View source ↗